Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS32015 in Relapsed or Refractory Multiple Myeloma
NCT05920876Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Dec 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS32015 in multiple myeloma (MM), sponsored by Qilu Pharmaceutical. Primary endpoints: Recommended Phase 2 Dose at 2 years, Incidence of adverse events at 2 years and 1 more. Status: unknown.
02
Drugs
QLS32015
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05920876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920876.